ImmunoCellular Therapeutics Ltd. announced additional data from its Phase I clinical trial evaluating ICT-107, the company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM). These new data showed a greater progression-free survival time in patients receiving ICT-107 than expected in this patient population. The median progression-free survival time (defined as the time between surgical tumor resection and tumor recurrence) in the 16 newly diagnosed patients enrolled in the trial was 19 months--12 months longer than the historical progression-free survival time of 6.9 months. Seven of these 16 patients continue to show no signs of tumor recurrence, three of whom have gone more than two years with no disease progression. With 80% of newly diagnosed patients (13 of the 16) still alive at a median time of 20 months, it is too early to determine the median overall survival time for this trial. Historically, only 26.5% patients survive two years with standard of care. ICT-107 was well tolerated, and no significant adverse events were reported during the trial. The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with GBM, the most common and aggressive form of brain cancer. The trial enrolled 19 patients--16 with newly-diagnosed and three with recurrent disease--who received ICT-107 in addition to standard treatment with radiation and temozolomide, a chemotherapy product that was until recently the only approved drug for GBM.

To discuss data from the company Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor

ImmunoCellular Therapeutics Ltd. announced that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate. The patent application, entitled 'Cell Surface Antigen for the Detection and Treatment of Small Cell Lung Cancer (SCLC), Pancreatic, and Colon Cancer ' relates to what the Company believes is a unique glycosidic composition of an antigen found on the surface of small cell lung cancer colon cancer and pancreatic cancer, and covers methods for detecting, diagnosing, monitoring, staging, imaging and/or treating the cancers. The patent application proposes to extend the intellectual property protection around ICT-109 by protecting proprietary glycosylated targets that are uniquely found in the aforementioned types of cancer and are associated with CEACAM5 and CEACAM6, two commonly targeted antigens in the public domain that are expressed in both healthy and malignant cells. These proprietary targets associated with CEACAM5 and CEACAM6, are uniquely expressed in cancerous cells, which allows ICT-109 to potentially differentiate between antigens present in normal benign tissue cells and those present in tumor cells, enabling the direct targeting of cancerous growths without harming healthy tissue.